Thalidomide 100mg

DRUG3 trials

Sponsors

Shanghai Pharmaceuticals Holding Co., Ltd, Henan Cancer Hospital, National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

Conditions

Ankylosing SpondylitisBeta-ThalassemiaEsophageal CarcinomaLung Cancer, Nonsmall Cell

Phase 2

Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

CompletedNCT02201043

Shanghai Pharmaceuticals Holding Co., LtdAnkylosing Spondylitis

Start: 2013-02-28End: 2015-02-28Updated: 2015-11-20

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

RecruitingNCT06231680

Henan Cancer HospitalEsophageal Carcinoma, Lung Cancer, Nonsmall Cell

Start: 2024-01-19End: 2025-09-30Target: 132Updated: 2024-03-29

Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.

CompletedNCT06239389

National Institute of Blood and Marrow Transplant (NIBMT), PakistanBeta-Thalassemia

Start: 2021-09-01End: 2022-03-03Updated: 2024-03-12

Related Papers

Comparison of Efficacy and Safety of Thalidomide vs Hydroxyurea in Thalassemia Patients: A Single-Centre Pilot Study

National Journal of Health Sciences2024-09-24